NACDS Foundation donors recognize leaders in community pharmacy
DENVER — Several National Association of Chain Drug Stores Foundation donors honored leaders in community pharmacy with contributions to the foundation at the 2012 NACDS Pharmacy and Technology Conference.
The awards recognize forward-thinking leaders who have shown a commitment to cultivating the future — and the present — of health care in community pharmacy.
The donations made in the name of honorees will help advance NACDS Foundation initiatives. The foundation also recognized pharmacy educators who have made significant contributions to patient care in the community pharmacy setting.
John Holcomb, VP healthcare operations at Target
IMS Health awarded the IMS Health Pharmacy Partnership Award to Target’s VP healthcare operations, John Holcomb. A contribution of $10,000 was made in Holcomb’s honor to the NACDS Foundation. The award recognizes a leader who values the importance of data in fact-based communication and will support foundation efforts to serve patient well-being.
Victor Curtis, Costco Wholesale doing business as Costco Pharmacies SVP pharmacy
Boehringer-Ingelheim Pharmaceuticals awarded the Boehringer-Ingelheim Pharmaceutical Alliance Award to Costco Wholesale doing business as Costco Pharmacies SVP pharmacy, Victor Curtis. The award commends leadership, commitment and service to patient care in community pharmacy. A $10,000 contribution was donated by Boehringer-Ingelheim Pharmaceuticals to the NACDS Foundation in Curtis’ name.
Matthew Machado, Massachusetts College of Pharmacy and Health Sciences associate professor of pharmacy practice
The NACDS Foundation Pharmacy Preceptor of the Year Award, supported by Apotex, recognized a pharmacy preceptor who has made significant contributions to patient care through the education of pharmacy students at Advanced Pharmacy Practice Experience rotations in a community pharmacy practice setting. The award recipient’s academic institution will receive a $5,000 stipend to fund future patient care projects or research.
Jeffery Goad, University of Southern California School of Pharmacy associate professor
The NACDS Foundation Community Pharmacy Faculty Award, supported by Abbott–Pharmaceutical Products Division, recognized a pharmacy school faculty member (full-time or shared faculty) who has made significant contributions to the practice of community pharmacy through innovations in patient care. The recipient’s academic institution will receive a $5,000 stipend to fund current or future research in the recipient’s area of community pharmacy practice.
“The NACDS Foundation, along with our generous donors, is proud to recognize those individuals who, day to day, are committed to improving pharmacy education, patient care and healthcare delivery in their communities,” stated Kathleen Jaeger, NACDS Foundation president. “We are honored to recognize these distinguished award recipients, and to support programs that will foster the next generation of patient care.”
Sun Pharma’s Caraco gets FDA OK to resume operations
MUMBAI, India — The Food and Drug Administration has determined that generic drug maker Caraco is in compliance with relevant paragraphs of the consent decree and may resume operations at its manufacturing facility and packaging sites in Detriot and Wixom, Mich., Caraco’s parent company Sun Pharmaceutical Industries said.
During their inspection, the FDA reviewed the certification reports for heart failure treatment Carvedilol USP, as well as antibiotic Paramomycin USP, and determined Caraco may resume production of only these two drugs.
"Manufacturing of other products from these sites, including those pending approval with [the FDA], will be subject to similar rigorous approval procedure," Sun Pharma said. "As a result, the increase in production at these sites and resultant revenue contribution is expected to be gradual."
FDA approves new combination pill for HIV treatment for some patients
FOSTER CITY, Calif. — The Food and Drug Administration has approved a new once-a-day combination pill to treat HIV-1 infection in adults who have never been treated for HIV infection.
Gilead Sciences received regulatory for its treatment, Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate). Stribild contains two previously approved HIV drugs plus two new drugs, elvitegravir and cobicistat. Elvitegravir is an HIV integrase strand transfer inhibitor, a drug that interferes with one of the enzymes that HIV needs to multiply. Cobicistat, a pharmacokinetic enhancer, inhibits an enzyme that metabolizes certain HIV drugs and is used to prolong the effect of elvitegravir. The combination of emtricitabine and tenofovir disoproxil fumarate — approved in 2004 and marketed as Truvada — blocks the action of another enzyme that HIV needs to replicate in a person’s body. Together, these drugs provide a complete treatment regimen for HIV infection.
"Through continued research and drug development, treatment for those infected with HIV has evolved from multi-pill regimens to single-pill regimens," said Edward Cox, director of the Office of Antimicrobial Products in FDA’s Center for Drug Evaluation and Research. "New combination HIV drugs like Stribild help simplify treatment regimens."